Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes

Investigational New Drugs

Volumn 32, Issue 1, 2014, Pages 14-24

  Friedland, Julie C ^a   Smith, Donald L ^a   Sang, Jim ^a   Acquaviva, Jaime ^a   He, Suqin ^a   Zhang, Chaohua ^a   Proia, David A ^a  

^a Synta Pharmaceuticals Corp   (United States)

Author keywords

Breast cancer; Cancer therapy; Ganetespib; Hsp90 inhibition

Indexed keywords

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INFLAMMATION; MICE, SCID; MOLECULAR TARGETED THERAPY; PROTEIN STABILITY; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TRIAZOLES; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899075777     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-9971-6     Document Type: Article

References (55)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E et al (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
2. Tran B, Bedard PL (2011) Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res 13:221
3. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS et al (2000) Molecular portraits of human breast tumours. Nature 406:747-752
4. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874 (Pubitemid 32878711)
5. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418-8423 (Pubitemid 36842560)
6. Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61-70
7. Rakha EA, Ellis IO (2009) Triple-negative/basal-like breast cancer: review. Pathology 41:40-47
8. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U et al (2009) Triple-negative breast cancer-current status and future directions. Ann Oncol 20:1913-1927
9. Brouckaert O, Wildiers H, Floris G, Neven P (2012) Update on triple-negative breast cancer: prognosis and management strategies. Int J Womens Health 4:511-520
10. Prat A, Parker JS, Fan C, Cheang MC, Miller LD et al (2012) Concordance among gene expression-based predictors for ERpositive breast cancer treated with adjuvant tamoxifen. Ann Oncol 23:2866-2873
11. Slamon DJ, Clark GM,Wong SG, Levin WJ, Ullrich A et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182 (Pubitemid 17231334)
12. De Mattos-Arruda L, Cortes J (2012) Advances in first-line treatment for patients with HER-2+ metastatic breast cancer. Oncologist 17:631-644
13. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429-4434 (Pubitemid 47219710)
14. Taipale M, Jarosz DF, Lindquist S (2010) HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 11:515-528
15. Whitesell L, Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5:761-772 (Pubitemid 41400776)
16. Trepel J, Mollapour M, Giaccone G, Neckers L (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10:537-549
17. Jhaveri K, Modi S (2012) HSP90 inhibitors for cancer therapy and overcoming drug resistance. Adv Pharmacol 65:471-517
18. Xu W, Neckers L (2007) Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin Cancer Res 13:1625-1629 (Pubitemid 46952925)
19. Banerji U (2009) Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 15:9-14
20. Taldone T, Gozman A, Maharaj R, Chiosis G (2008) Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol 8:370-374
21. Li Y, Zhang T, Schwartz SJ, Sun D (2009) New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential. Drug Resist Updat 12:17-27
22. Basso AD, Solit DB, Munster PN, Rosen N (2002) Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 21:1159-1166 (Pubitemid 34185232)
23. Wong C, Chen S (2009) Heat shock protein 90 inhibitors: new mode of therapy to overcome endocrine resistance. Cancer Res 69:8670-8677
24. Jensen MR, Schoepfer J, Radimerski T, Massey A, Guy CT et al (2008) NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res 10:R33
25. Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI et al (2009) Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A 106:8368-8373
26. Mehta PP, Whalen P, Baxi SM, Kung PP, Yamazaki S et al (2011) Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90. Clin Cancer Res 17:5432-5442
27. Scaltriti M, Serra V, Normant E, Guzman M, Rodriguez O et al (2011) Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer. Mol Cancer Ther 10:817-824
28. Chandarlapaty S, Sawai A, Ye Q, Scott A, Silinski M et al (2008) SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res 14:240-248 (Pubitemid 351378001)
29. Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S et al (2011) HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res 17:5132-5139
30. YingW, Du Z, Sun L, Foley KP, Proia DA et al (2012) Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 11:475-484
31. Proia DA, Sang J, He S, Smith DL, Sequeira M et al (2012) Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in nonsmall cell lung cancer models. Invest New Drugs 30:2201-2209
32. Acquaviva J, Smith DL, Sang J, Friedland JC, He S et al (2012) Targeting KRAS mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib. Mol Cancer Ther 11:2633-2643
33. Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ et al (2012) Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of nonsmall cell lung cancer. Clin Cancer Res 18:4973-4985
34. He S, Zhang C, Shafi AA, Sequeira M, Acquaviva J et al (2013) Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. Int J Oncol 42:35-43
35. Proia DA, Foley KP, Korbut T, Sang J, Smith D et al (2011) Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. PLoS One 6:e18552
36. Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic Vet al (2013) A multicenter Phase II study of ganetespib monotherapy in patients with genotypically-defined advanced non-small cell lung cancer. Clin Cancer Res. doi:10.1158/1078-0432.CCR-12-3381
37. Harrison H, Farnie G, Howell SJ, Rock RE, Stylianou S et al (2010) Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res 70:709-718
38. Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M et al (2006) Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 5:2512-2521 (Pubitemid 44650915)
39. Mass RD, Press MF, Anderson S, Cobleigh MA, Vogel CL et al (2005) Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 6:240-246 (Pubitemid 47050800)
40. Yamauchi H, Woodward WA, Valero V, Alvarez RH, Lucci A et al (2012) Inflammatory breast cancer: what we know and what we need to learn. Oncologist 17:891-899
41. Sinclair S, Swain SM (2010) Primary systemic chemotherapy for inflammatory breast cancer. Cancer 116:2821-2828
42. Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S et al (2010) Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin 60:351-375
43. Pratt WB, Galigniana MD, Morishima Y, Murphy PJ (2004) Role of molecular chaperones in steroid receptor action. Essays Biochem 40:41-58 (Pubitemid 38901166)
44. Rao RD, Cobleigh MA (2012) Adjuvant endocrine therapy for breast cancer. Oncology (Williston Park) 26:41-547
45. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717
46. Bachleitner-Hofmann T, Pichler-Gebhard B, Rudas M, Gnant M, Taucher S et al (2002) Pattern of hormone receptor status of secondary contralateral breast cancers in patients receiving adjuvant tamoxifen. Clin Cancer Res 8:3427-3432 (Pubitemid 35340717)
47. Beliakoff J, Bagatell R, Paine-Murrieta G, Taylor CW, Lykkesfeldt AE et al (2003) Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors. Clin Cancer Res 9:4961-4971 (Pubitemid 37323303)
48. Neckers L, Workman P (2012) Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 18:64-76
49. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G et al (2010) Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:1124-1130
50. Garrett JT, Arteaga CL (2011) Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol Ther 11:793-800
51. Chandarlapaty S, Scaltriti M, Angelini P, Ye Q, Guzman M et al (2010) Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene 29:325-334
52. Baselga J, Semiglazov V, Maniknas G (2007) Efficacy of neoadjuvant trastuzumab in patients with inflammatory breast cancer (IBC): Data from the NOAH (neoadjuvant herceptin) phase III trial. Eur J Cancer 5(Suppl):193
53. Pierga JY, Petit T, Delozier T, Ferrero JM, Campone M et al (2012) Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. Lancet Oncol 13:375-384
54. Robertson FM (2011) Gene amplification of anaplastic lymphoma kinase in inflammatory breast cancer. Mol Cancer Ther 10:PR-4
55. Sang J, Acquaviva J, Friedland JC, Smith D, Sequeira M et al (2013) Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov 3:430-443